-
The large-scale inter-provincial volume procurement has officially started...
Time of Update: 2021-11-14
On November 4, the Guangdong Pharmaceutical Trade Center issued the official version of the "Guangdong Union Amoxicillin and Other 45 Pharmaceutical Groups Procurement Documents", announcing the offic
-
The Chinese medicine market is showing steady growth. The industry: facing a good time that has never happened before
Time of Update: 2021-11-14
Promoted by favorable national policies and increasing demand, the market size of the Chinese medicine industry has shown a steady growth trend .
Data show that from 2016 to 2020, the compound annual growth rate of the market size of China's traditional Chinese medicine industry will reach 19.
-
Say no to monopoly APIs!
Time of Update: 2021-11-14
On April 15, the State Municipal Supervision Bureau again notified that a large pharmaceutical company was fined 3% of its sales in 2018, totaling 764 million yuan, for its violations of the anti-monopoly law to implement a monopoly agreement.
-
[2021 ASH] APG-2575, a selective inhibitor of Bcl-2, was selected for two studies, and the Chinese clinical study showed CR
Time of Update: 2021-11-14
Suzhou, China and Rockville, Maryland, U. S. November 5, 2021/PRNewswire/ Pharmaceutical (6855. HK) announced today that the company has three new drugs under development (oribatinib, APG-2575, APG-1
-
Innovative Chinese medicines welcome the outbreak, and a large number of Class 1 new drugs have been applied for clinical application and marketing
Time of Update: 2021-11-14
Recently, Henan Tianfang Pharmaceutical Traditional Chinese Medicine/Shenzhen Shasong Lesheng received the CDE acceptance for the marketing application of Brainshang Lesheng Granules submitted in the new drug category 1.
-
Kangfang Bio-PD-1/VEGF Double Antibody Approved for Phase II Clinical Treatment of Non-Small Cell Lung Cancer
Time of Update: 2021-11-14
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn November 2, Kangfang Biological announced that the new tumor immunotherapy drug AK112 (PD-1/VEGF bispecific antibody) was approved by CDE, and the development of single-drug or combined chemotherapy neoadjuvant/adjuvant therapy can cut non-small cell lung cancer (NSCLC).
-
Undertake the spillover effect and continue to invest in China, Boehringer Ingelheim participated in the 4th CIIE to practice the concept of "same health"
Time of Update: 2021-11-14
Shanghai, November 2, 2021/PRNewswire/ - At the 4th CIIE, Boehringer Ingelheim, a world-renowned R&D-driven biopharmaceutical company, will bring 500+100 square meters of double booths to fully demonstrate that companies are promoting mankind And innovations in animal health .
-
National talks about drugs "should be fully equipped". The top three hospitals are no less than 30%!
Time of Update: 2021-11-14
As the new year of national talks approaches, on November 2, Zhejiang Medical Insurance Bureau issued the "Notice on Implementing the "Dual Channel" Management Mechanism for Drugs in National Medical
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Creatine Phosphate Sodium for Injection (No. 105 of 2021)
Time of Update: 2021-11-14
According to the results of the adverse drug reaction assessment, in order to further ensure the safety of the public use of drugs, the State Drug Administration has decided to uniformly revise and improve the contents of the instructions for creatine phosphate sodium for injection .
-
The transformation to "intelligent manufacturing" has become the general trend of the development of the pharmaceutical industry!
Time of Update: 2021-11-14
For Hongdou Group's huge investment in building a smart factory project for high-end complex anti-tumor preparations, the industry believes that this is mainly because the pharmaceutical industry is facing the challenge of large-scale production.
-
Announcement of the State Food and Drug Administration on Revising the Insert Sheets of 4 Kinds of Drugs including Cold and Clearing Heat Preparations (No. 88 of 2021)
Time of Update: 2021-11-14
According to the evaluation results of adverse drug reactions, in order to further ensure the safety of the public use of drugs, the National Medical Products Administration has decided to make unified revisions to the four instructions of the cold and heat-clearing preparations [Adverse Reactions], [Contraindications] and [Precautions] .
-
Eli Lilly and the U.S. government sign a $1.3 billion COVID-19 antibody supply agreement
Time of Update: 2021-11-14
In August of this year, the FDA resumed the authorization of Eli Lilly's neutralizing antibody, but only allowed to use it in states, territories and US jurisdictions where the prevalence of mutants resistant to double antibody therapy is low (less than 5%).
-
Two drugs from China Resources Double-Crane's wholly-owned subsidiaries obtained "Drug Registration Certificate"
Time of Update: 2021-11-14
On November 1, China Resources Double-Crane issued an announcement stating that its wholly-owned subsidiary, China Resources SECCO, had recently received amlodipine and atorvastatin calcium tablets and sildenafil citrate tablets from the National Food and Drug Administration.
-
With a series of policies vigorously boosting the development of Chinese medicine, the authentic medicinal material industry has a great opportunity
Time of Update: 2021-11-14
For example, as early as December 18, 2018, the Ministry of Agriculture and Rural Affairs of the United Nations National Drug Administration and the State Administration of Traditional Chinese Medicine jointly issued the "National Authentic Medicinal Material Production Base Construction Plan (2018-2025)", which is a guide Important documents for the development of the Chinese herbal medicine industry in the next few years are also important measures to implement the Chinese Medicine Law .
-
once a week!
Time of Update: 2021-11-14
ArticleMedicine GuanlanRecently, the Chinese drug clinical trial registration and information disclosure platform showed that Novo Nordisk has launched a trial in China to study how NNC0174-0833 (cagrilintide) can play a role in normal weight, overweight or obese Chinese population .
-
Traditional Chinese medicine decoction pieces are frequently found to be unqualified. How should pharmaceutical companies ensure quality and safety?
Time of Update: 2021-11-14
Therefore, pharmaceutical equipment companies also need to continue to carry out technological innovation, while promoting the high-quality development of traditional Chinese medicine decoction pieces, continuously improve their own competitiveness .
-
Generic drugs will remain the focus in the next ten years, and there will still be a broad market
Time of Update: 2021-11-14
Generic drugs have important economic and social benefits in reducing medical expenditures, improving the availability of medicines, and improving the level of medical services . It is understood t
-
Zhou Song, director of Sinopharm Accord, resigns
Time of Update: 2021-11-14
On November 2, Sinopharm unanimously announced that the company’s board of directors had recently received a written resignation report from director Zhou Song . Zhou Song applied to resign as a dire
-
The National Medical Insurance Administration determines the rules for renewing contracts with volume purchases
Time of Update: 2021-11-14
All provinces, autonomous regions, municipalities directly under the Central Government, and Xinjiang Production and Construction Corps Medical Insurance Bureau: To implement the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Mass Procurement of Drugs" (Guobanfa [2021] No.
-
Announcement of the State Drug Administration on Revising the Instructions for Oxaliplatin Preparations (No. 102 of 2021)
Time of Update: 2021-11-14
The marketing authorization holders of the above-mentioned drugs shall be in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, in accordance with the requirements for the revision of the oxaliplatin preparation instructions (see attachment), before November 22, 2021 Report to the provincial drug supervision and administration department for the record .
